A new type of immunotherapy making use of the immune system’s ‘natural killer cells’ could offer potential against a range of cancers that can evade current treatments, early results from a phase I trial suggest.

Scientists have, for the first time, recreated an assembly of proteins known as the β-catenin destruction complex in the test tube. This is a long-awaited step in cancer research, as mutations in this destruction complex are found in a large percentage of bowel and other cancers.

Scientists can use genetic ‘weather forecasting’ to predict how long it will take for bowel cancer to evolve resistance to a drug before a patient has even started treatment, a new study has shown.